Caption Management, LLC Vertex Pharmaceuticals Inc Call Options Transaction History

Caption Management, LLC

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$460.0 - $505.78 $23 Million - $25.3 Million	50,000 New	50,000 $23.3 Million
Q4 2023 Feb 14, 2024	SELL	$343.0 - $410.68 $7.89 Million - $9.45 Million	-23,000 Reduced 79.31%	6,000 $2.44 Million
Q3 2023 Nov 14, 2023	BUY	$338.18 - $362.46 $9.81 Million - $10.5 Million	29,000 New	29,000 $10.1 Million
Q4 2021 Feb 11, 2022	SELL	$177.01 - $223.45 $2.66 Million - $3.35 Million	-15,000 Reduced 23.08%	50,000 $11 Million
Q3 2021 Nov 12, 2021	BUY	$181.39 - $202.99 $11.8 Million - $13.2 Million	65,000 New	65,000 $11.8 Million
Q4 2020 Feb 16, 2021	SELL	$207.01 - $276.09 $1.66 Million - $2.21 Million	-8,000 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$255.65 - $303.1 $2.05 Million - $2.42 Million	8,000 New	8,000 $2.18 Million
Q3 2019 Nov 14, 2019	SELL	$166.23 - $187.09 $4.16 Million - $4.68 Million	-25,000 Closed	0 $0
Q2 2019 Aug 13, 2019	SELL	$164.61 - $190.37 $1.65 Million - $1.9 Million	-10,000 Reduced 28.57%	25,000 $4.58 Million
Q1 2019 May 14, 2019	BUY	$163.73 - $194.7 $5.73 Million - $6.81 Million	35,000 New	35,000 $6.44 Million

1,724

221M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $105B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Caption Management, LLC with notifications on news.